SG Americas Securities
URGN icon

SG Americas Securities’s UroGen Pharma URGN Stock Holding History

SG Americas Securities’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.5M Buy
2,052,906
+395,060
+24% +$10.7M 0.04% 257
2026
Q1 		$29.8M Buy
1,657,846
+280,199
+20% +$5.62M 0.03% 410
2025
Q4 		$32.3M Buy
1,377,647
+220,264
+19% +$4.78M 0.04% 342
2025
Q3 		$23.1M Buy
1,157,383
+8,302
+0.7% +$149K 0.08% 167
2025
Q2 		$15.7M Buy
1,149,081
+986,567
+607% +$9.47M 0.07% 223
2025
Q1 		$1.8M Buy
162,514
+142,245
+702% +$1.52M 0.01% 838
2024
Q4 		$216K Buy
20,269
+6,207
+44% +$74.3K ﹤0.01% 2080
2024
Q3 		$179K Buy
+14,062
New +$209K ﹤0.01% 2592
2024
Q1 		– Sell
-8,707
Closed -$131K – 3461
2023
Q4 		$131K Buy
+8,707
New +$113K ﹤0.01% 2530
2021
Q4 		– Sell
-10,318
Closed -$174K – 3823
2021
Q3 		$174K Buy
+10,318
New +$164K ﹤0.01% 3320
2021
Q2 		– Sell
-5,235
Closed -$102K – 3259
2021
Q1 		$102K Sell
5,235
-51,009
-91% -$1.08M ﹤0.01% 3077
2020
Q4 		$1.01M Sell
56,244
-5,492
-9% -$115K 0.01% 1534
2020
Q3 		$1.19M Sell
61,736
-69,914
-53% -$1.58M 0.01% 1076
2020
Q2 		$3.44M Buy
131,650
+30,053
+30% +$734K 0.03% 522
2020
Q1 		$1.81M Buy
101,597
+51,257
+102% +$1.38M 0.02% 865
2019
Q4 		$1.68M Buy
50,340
+585
+1% +$16K 0.02% 934
2019
Q3 		$1.19M Buy
+49,755
New +$1.63M 0.01% 1298

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

SG Americas Securities's URGN Position: Q2 2026 in Review

SG Americas Securities increased its UroGen Pharma (URGN) stake by 24% in Q2 2026, buying an estimated $10.7M and bringing the position to 2,052,906 shares worth $75.5M. The position accounts for 0.04% of the portfolio, ranked #257.

SG Americas Securities first reported a position in URGN in Q3 2019 and has held it in 17 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • SG Americas Securities held 2,052,906 shares of UroGen Pharma worth $75.5M as of Q2 2026.
  • SG Americas Securities bought 395,060 UroGen Pharma shares in Q2 2026, an estimated $10.7M.
  • UroGen Pharma made up 0.04% of SG Americas Securities's portfolio in Q2 2026, its #257 holding.
  • SG Americas Securities first reported a position in UroGen Pharma in Q3 2019 and has held it in 17 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.